GlassScriptPhysician profile
Melissa Darling
NPI 1558686378
$9,690.22
in general payments reported to CMS, 2019-2025
28 companies · $3,227 in 2025
The $3,227 reported for 2025 was more than what 85% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $72.48 · 2020: $82.67 · 2021: $660 · 2022: $1,293 · 2023: $1,823 · 2024: $2,531 · 2025: $3,227.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,344 · Education: $238.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,343.94 |
| Education | $237.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,505.96 | 2020-2025 | Skyrizi, Rinvoq |
| Janssen Biotech, INC. | $1,479.18 | 2021-2025 | Tremfya |
| Lilly USA, LLC | $980.14 | 2022-2025 | Taltz, Olumiant, Ebglyss |
| Amgen INC. | $705.70 | 2021-2025 | Otezla, Enbrel, Otezla |
| Novartis Pharmaceuticals Corporation | $672.56 | 2022-2025 | |
| Genzyme Corporation | $641.16 | 2023-2025 | |
| Incyte Corporation | $625.57 | 2021-2025 | Opzelura |
| Sun Pharmaceutical Industries INC. | $615.36 | 2020-2025 | Absorica Ld, Winlevi, Ilumya |
| Pfizer INC. | $419.26 | 2019-2025 | |
| Ucb, INC. | $309.34 | 2023-2025 | Bimzelx, Cimzia |
| Dermavant Sciences, INC. | $297.26 | 2023-2024 | Vtama |
| Regeneron Healthcare Solutions, INC. | $278.07 | 2022-2025 | Dupixent |
| Leo Pharma INC. | $162.85 | 2022-2025 | Adbry |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $135.95 | 2019-2025 | Jublia, Arazlo, Siliq |
| Paratek Pharmaceuticals, INC. | $108.78 | 2022-2024 | Nuzyra |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kerecis Limited | $105.71 | 2023-2024 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide |
| E.R. Squibb & Sons, L.L.C. | $103.59 | 2024-2025 | Sotyktu |
| Organon LLC | $100.76 | 2025 | Vtama |
| Arcutis Biotherapeutics, INC. | $98.33 | 2023-2025 | Zoryve |
| Galderma Laboratories, L.P. | $92.08 | 2021-2025 | Nemluvio |
| Botanix Sb INC | $45.53 | 2025 | Sofdra |
| Organogenesis INC. | $40.38 | 2024 | Puraply Am |
| Fresenius Kabi USA, LLC | $40.12 | 2023 | Idacio |
| Boehringer Ingelheim Pharmaceuticals, INC. | $39.43 | 2025 | Spevigo |
| Alexion Pharmaceuticals, INC. | $25.83 | 2024 | Koselugo |
| Sandoz INC. | $23.53 | 2023 | Hyrimoz |
| Almirall LLC | $22.48 | 2022 | |
| Celgene Corporation | $15.31 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Darling listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.